Curis, Inc. is a biotechnology company, which is focused on the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CRIS
CUSIP23126910
Phone617-503-6500
Debt
Debt-to-Equity Ratio2.24
Current Ratio3.60
Quick Ratio3.60
Price-To-Earnings
Trailing P/E Ratio-1.16
Forward P/E Ratio-1.26
P/E GrowthN/A
Sales & Book Value
Annual Sales$9.90 million
Price / Sales6.96
Cash FlowN/A
Price / CashN/A
Book Value$0.73 per share
Price / Book2.85
Profitability
EPS (Most Recent Fiscal Year)($1.80)
Net Income$-53,310,000.00
Net Margins-472.13%
Return on Equity-247.46%
Return on Assets-68.71%
Miscellaneous
Employees55
Outstanding Shares33,130,000
Curis (NASDAQ:CRIS) Frequently Asked Questions
What is Curis' stock symbol?
Curis trades on the NASDAQ under the ticker symbol "CRIS."
When did Curis' stock split? How did Curis' stock split work?
Shares of Curis reverse split on Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 29th 2018. An investor that had 100 shares of Curis stock prior to the reverse split would have 20 shares after the split.
How were Curis' earnings last quarter?
Curis, Inc. (NASDAQ:CRIS) announced its quarterly earnings data on Thursday, May, 3rd. The biotechnology company reported ($0.35) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.10. The biotechnology company earned $2.47 million during the quarter, compared to analysts' expectations of $2.30 million. Curis had a negative net margin of 472.13% and a negative return on equity of 247.46%. View Curis' Earnings History.
When is Curis' next earnings date?
What price target have analysts set for CRIS?
2 equities research analysts have issued 1-year price objectives for Curis' stock. Their predictions range from $30.00 to $35.00. On average, they expect Curis' stock price to reach $32.50 in the next year. View Analyst Ratings for Curis.
Who are some of Curis' key competitors?
Some companies that are related to Curis include Allena Pharmaceuticals (ALNA), Jounce Therapeutics (JNCE), Agenus (AGEN), Arsanis (ASNS), Nantkwest (NK), ADMA Biologics (ADMA), Compugen (CGEN), Fennec Pharmaceuticals (FENC), Organovo (ONVO), Eiger Biopharmaceuticals (EIGR), Krystal Biotech (KRYS), Pluristem Therapeutics (PSTI), Aptose Biosciences (APTO), Cidara Therapeutics (CDTX) and Genocea Biosciences (GNCA).
Who are Curis' key executives?
Curis' management team includes the folowing people:
- Ali Fattaey, President, Chief Executive Officer & Director
- James E. Dentzer, COO, CFO, CAO, Secretary & Treasurer
- David Tuck, Chief Medical Officer & Senior Vice President
Has Curis been receiving favorable news coverage?
Press coverage about CRIS stock has been trending somewhat positive recently, Accern Sentiment reports. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Curis earned a media sentiment score of 0.13 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 47.24 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Curis' major shareholders?
Curis' stock is owned by a number of of institutional and retail investors. Top institutional investors include First Eagle Investment Management LLC (15.04%), BlackRock Inc. (5.80%), Arnhold LLC (1.76%), GSA Capital Partners LLP (1.16%), Sio Capital Management LLC (0.50%) and Candriam Luxembourg S.C.A. (0.48%). Company insiders that own Curis stock include Ali PhD Fattaey, Discovery Technologie Aurigene, James R Mcnab and Marc Rubin. View Institutional Ownership Trends for Curis.
Which institutional investors are selling Curis stock?
Which institutional investors are buying Curis stock?
CRIS stock was bought by a variety of institutional investors in the last quarter, including Arnhold LLC, GSA Capital Partners LLP, Sio Capital Management LLC and Candriam Luxembourg S.C.A.. Company insiders that have bought Curis stock in the last two years include Ali PhD Fattaey, Discovery Technologie Aurigene and Marc Rubin. View Insider Buying and Selling for Curis.
How do I buy shares of Curis?
Shares of CRIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Curis' stock price today?
One share of CRIS stock can currently be purchased for approximately $2.08.
How big of a company is Curis?
Curis has a market capitalization of $70.89 million and generates $9.90 million in revenue each year. The biotechnology company earns $-53,310,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. Curis employs 55 workers across the globe.
How can I contact Curis?
Curis' mailing address is 4 MAGUIRE ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 617-503-6500 or via email at [email protected]
MarketBeat Community Rating for Curis (CRIS)
MarketBeat's community ratings are surveys of what our community members think about Curis and other stocks. Vote "Outperform" if you believe CRIS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRIS will underperform the S&P 500 over the long term. You may vote once every thirty days.
